PROTEIN SYNTHESIS
The control of protein synthesis in health and disease
| Coordinatore | UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 100˙000 € |
| EC contributo | 100˙000 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-IRG-2008 |
| Funding Scheme | MC-IRG |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-02-05 - 2013-02-04 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
UK (SOUTHAMPTON) | coordinator | 100˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Protein synthesis is a key process in living cells, being required for cells to grow, divide, and respond to changing conditions, as well as being critical in gene expression. However, protein synthesis in an expensive process, using a great of energy and amino acids. It is therefore tightly controlled. This involves the regulation, by phosphorylation, of proteins involved in protein synthesis (‘translation factors’) and mRNA-binding proteins. My laboratory studies the roles of these proteins and the protein kinases that act upon them in regulating protein synthesis in mammalian cells. I am particularly interested in the mTOR (mammalian target of rapamycin) pathway, which is regulated by amino acids and hormones and controls several steps in protein synthesis. A major goal of this project is to achieve a more complete understanding of mTOR signalling and to establish how different signalling pathways and translation factors work together to control protein synthesis. This research will extend our knowledge of a key biological process also help optimize production of biological drugs’, a major interest in the pharmaceutical industry. My laboratory also has a strong interest in the mechanisms by which defects in the translational machinery or in its control lead to human diseases. For example, dysregulation of mTOR signalling leads to cancer and heart disease. We will explore the molecular mechanisms involved in this. Defects in a key translation factor (‘eIF2B’) cause a severe neurodegenerative disease (‘vanishing white matter’). We will employ multiple complementary approaches to understand how problems in protein synthesis lead to these diseases. This will provide valuable information for treating or managing them. Lastly, faulty control of the synthesis of proteins called cytokines leads to inflammatory disease. I will explore the mechanisms that normally control cytokine synthesis, which may lead to new opportunities for treating inflammatory diseases.'